ABSTRACT:

Breast cancer is one complex disease with different molecular and cellular changes. The pathophysiologic features of cancer are based on genetic, hormonal, and environmental influences; thus the disease has several subtypes that differ in behavior and response to treatment. The pathophysiology of breast cancer includes a number of factors that interplay among genetic mutations, hormonal influences, and microenvironment factors. Although these have been greatly elucidated by current research, more detailed understanding is requisite for further enhancement in the outcomes of treatment and development of individualized therapies. New technologies and methodologies are quick to surface; however, they promise better deciphering of breast cancer complexity and consequently better routes for interventions aimed at maximum efficacy. This literature review serves to synthesize the most recent findings on the pathophysiology of breast cancer in light of its complexity, identification of gaps in the current state of knowledge, and suggestions for directions future research should take.

REFERENCES :

1) Almeida, Maria., Laurent, M.., Dubois, V.., Claessens, F.., O’Brien, C.., Bouillon, R.., Vanderschueren, D.., & Manolagas, S.. (2017). Estrogens and Androgens in Skeletal Physiology and Pathophysiology.. Physiological reviews , 97 1 , 135-187 . http://doi.org/10.1152/PHYSREV.00033.2015 
2) Beral, V.., Reeves, G.., Bull, D.., & Green, J.. (2011). Breast Cancer Risk in Relation to the Interval Between Menopause and Starting Hormone Therapy. JNCI Journal of the National Cancer Institute , 103 , 296 – 305 . http://doi.org/10.1093/jnci/djq527
3) Bray, F.., Ferlay, J.., Soerjomataram, I.., Siegel, R.., Torre, Lindsey A.., & Jemal, A.. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians , 68 . http://doi.org/10.3322/caac.21492
4) Couch, F.., Hart, S.., Sharma, Priyanka., Toland, A.., Wang, Xianshu., Miron, P.., Olson, J.., Godwin, A.., Pankratz, V.., Olswold, Curtis L.., Slettedahl, S.., Hallberg, Emily J.., Guidugli, L.., Dávila, Jaime I.., Beckmann, M.., Janni, W.., Rack, B.., Ekici, A.., Slamon, D.., Konstantopoulou, I.., Fostira, F.., Vratimos, A.., Fountzilas, G.., Pelttari, Liisa M.., Tapper, W.., Durcan, L.., Cross, S.., Pilarski, R.., Shapiro, C.., Klemp, J.., Yao, S.., Garber, J.., Cox, A.., Brauch, H.., Ambrosone, C.., Nevanlinna, H.., Yannoukakos, D.., Slager, S.., Vachon, C.., Eccles, D.., Fasching, P.., & Fasching, P.. (2015). Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology , 33 4 , 304-11 . http://doi.org/10.1200/JCO.2014.57.1414
5) Dawood, S.., Broglio, K.., Buzdar, A.., Hortobagyi, G.., & Giordano, S.. (2010). Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology , 28 1 , 92-8 . http://doi.org/10.1200/JCO.2008.19.9844
6) DeSantis, C.., Fedewa, S.., Sauer, Ann Goding., Kramer, J.., Smith, Robert A.., & Jemal, A.. (2016). Breast cancer statistics, 2015: Convergence of incidence rates between black and white women. CA: A Cancer Journal for Clinicians , 66 . http://doi.org/10.3322/caac.21320
7) DeSantis, C.., Ma, Jiemin., Bryan, Leah N.., & Jemal, A.. (2014). Breast cancer statistics, 2013. CA: A Cancer Journal for Clinicians , 64 . http://doi.org/10.3322/caac.21203
8) DeSantis, C.., Ma, Jiemin., Gaudet, M.., Newman, L.., Miller, K. D.., Sauer, Ann Goding., Jemal, A.., & Siegel, R.. (2019). Breast cancer statistics, 2019. CA: A Cancer Journal for Clinicians , 69 . http://doi.org/10.3322/caac.21583
9) DeSantis, C.., Ma, Jiemin., Sauer, Ann Goding., Newman, L.., & Jemal, A.. (2017). Breast cancer statistics, 2017, racial disparity in mortality by state. CA: A Cancer Journal for Clinicians , 67 . http://doi.org/10.3322/caac.21412
10) Feng, Ruimei., Zong, Yi-Nan., Cao, Su-Mei., & Xu, R.. (2019). Current cancer situation in China: good or bad news from the 2018 Global Cancer Statistics?. Cancer Communications , 39 . http://doi.org/10.1186/s40880-019-0368-6
11) Hershman, D.., Kushi, L.., Shao, T.., Buono, D.., Kershenbaum, A.., Tsai, W.., Fehrenbacher, L.., Gomez, S.., Miles, Sunita Q., & Neugut, A.. (2010). Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology , 28 27 , 4120-8 . http://doi.org/10.1200/JCO.2009.25.9655
12) Jemal, A.., Bray, F.., Center, Melissa M.., Ferlay, J.., Ward, Elizabeth E.., & Forman, D.. (2011). Global cancer statistics. CA: A Cancer Journal for Clinicians , 61 . http://doi.org/10.3322/caac.20107
13) Keren, Leeat., Bossé, M.., Marquez, Diana., Angoshtari, Roshan., Jain, Samir., Varma, S.., Yang, Soo-Ryum., Kurian, A.., Valen, D. V.., West, Robert., Bendall, S.., & Angelo, Michael. (2018). A Structured Tumor-Immune Microenvironment in Triple Negative Breast Cancer Revealed by Multiplexed Ion Beam Imaging. Cell , 174 , 1373-1387.e19 . http://doi.org/10.1016/j.cell.2018.08.039
14) Łukasiewicz, Sergiusz., Czeczelewski, Marcin., Forma, Alicja., Baj, J.., Sitarz, R.., & Stanisławek, A.. (2021). Breast Cancer—Epidemiology, Risk Factors, Classification, Prognostic Markers, and Current Treatment Strategies—An Updated Review. Cancers , 13 . http://doi.org/10.3390/cancers13174287
15) Minckwitz, G. von., Huang, Chiun-Sheng., Mano, M.., Loibl, S.., Mamounas, E.., Untch, M.., Wolmark, N.., Rastogi, P.., Schneeweiss, A.., Redondo, A.., Fischer, H.., Jacot, W.., Conlin, A.., Arce‐Salinas, C.., Wapnir, I.., Jackisch, C.., DiGiovanna, M.., Fasching, P.., Crown, J.., Wülfing, P.., Shao, Z.., Caremoli, E. R.., Wu, Haiyan., Lam, L.., Tesarowski, D.., Smitt, M.., Douthwaite, Hannah., Singel, S.., & Geyer, C.. (2019). Trastuzumab Emtansine for Residual Invasive HER2‐Positive Breast Cancer. The New England Journal of Medicine , 380 , 617–628 . http://doi.org/10.1056/NEJMoa1814017
16) Modi, S.., Jacot, W.., Yamashita, T.., Sohn, J.., Vidal, M.., Tokunaga, E.., Tsurutani, J.., Ueno, N.., Prat, A.., Chae, Y.., Lee, K.., Niikura, N.., Park, Yeon-Hee., Xu, Bing-he., Wang, Xiao-juan., Gil-Gil, M.., Li, Wei., Pierga, J.., Im, S.., Moore, H.., Rugo, H.., Yerushalmi, R.., Zagouri, F.., Gombos, A.., Kim, Sung-Bae., Liu, Qiang., Luo, T.., Saura, C.., Schmid, P.., Sun, T.., Gambhire, D.., Yung, L.., Wang, Yibin., Singh, Jasmeet., Vitazka, P.., Meinhardt, G.., Harbeck, N.., & Cameron, D.. (2022). Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer. New England Journal of Medicine . http://doi.org/10.1056/nejmoa2203690
17) Murthy, R.., Loi, S.., Okines, A.., Paplomata, E.., Hamilton, E.., Hurvitz, S.., Lin, N.., Borges, V.., Abramson, V.., Anders, C.., Bedard, P.., Oliveira, Mafalda., Jakobsen, E.., Bachelot, T.., Shachar, S. S.., Müller, V.., Braga, S.., Duhoux, F.., Greil, R.., Cameron, D.., Carey, L.., Curigliano, G.., Gelmon, K.., Hortobagyi, G.., Krop, I.., Loibl, S.., Pegram, M.., Slamon, D.., Palanca-Wessels, M. C.., Walker, L.., Feng, W.., & Winer, E.. (2019). Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer.. The New England journal of medicine . http://doi.org/10.1056/NEJMoa1914609
18) Semenza, G.. (2016). The hypoxic tumor microenvironment: A driving force for breast cancer progression.. Biochimica et biophysica acta , 1863 3 , 382-391 . http://doi.org/10.1016/j.bbamcr.2015.05.036
19) Slamon, D.., Eiermann, W.., Robert, N.., Pieńkowski, T.., Martín, Miguel., Press, M.., Mackey, J.., Glaspy, J.., Chan, A.., Pawlicki, M.., Pintér, T.., Valero, V.., Liu, Mei-Ching., Sauter, G.., Minckwitz, G. von., Visco, F.., Bée, V.., Buyse, M.., Bendahmane, B.., Tabah-Fisch, I.., Lindsay, M.., Riva, A.., & Crown, J.. (2011). Adjuvant trastuzumab in HER2-positive breast cancer.. The New England journal of medicine , 365 14 , 1273-83 . http://doi.org/10.1056/NEJMoa0910383
20) Sung, H.., Ferlay, J.., Siegel, R.., Laversanne, M.., Soerjomataram, I.., Jemal, A.., & Bray, F.. (2021). Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians , 71 , 209 – 249 . http://doi.org/10.3322/caac.21660
21) Torre, Lindsey A.., Bray, F.., Siegel, R.., Ferlay, J.., Lortet-Tieulent, J.., & Jemal, A.. (2015). Global cancer statistics, 2012. CA: A Cancer Journal for Clinicians , 65 . http://doi.org/10.3322/caac.21262
22) Toy, Weiyi., Shen, Yang., Won, H.., Green, B.., Sakr, R.., Will, Marie., Li, Zhiqiang., Gala, K.., Fanning, S.., King, T.., Hudis, C.., Chen, David J.., Taran, T.., Hortobagyi, G.., Greene, G.., Berger, M.., Baselga, J.., & Chandarlapaty, S.. (2013). ESR1 ligand binding domain mutations in hormone-resistant breast cancer. Nature genetics , 45 , 1439 – 1445 . http://doi.org/10.1038/ng.2822
23) Verma, S.., Miles, D.., Gianni, L.., Krop, I.., Welslau, M.., Baselga, J.., Pegram, M.., Oh, D.., Diéras, V.., Guardino, E.., Fang, L.., Lu, Michael W.., Olsen, S.., & Blackwell, K.. (2012). Trastuzumab emtansine for HER2-positive advanced breast cancer.. The New England journal of medicine , 367 19 , 1783-91 . http://doi.org/10.1056/NEJMoa1209124
24) Vogel, C.., Cobleigh, M.., Tripathy, D.., Gutheil, J.., Harris, L.., Fehrenbacher, L.., Slamon, D.., Murphy, M.., Novotny, W.., Burchmore, M.., Shak, S.., Stewart, S.., & Press, M.. (2023). Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer. Journal of Clinical Oncology , 41 , 1638 – 1645 . http://doi.org/10.1200/jco.22.02516
25) Voorwerk, L.., Slagter, M.., Horlings, H.., Sikorska, K.., Vijver, K. K. van de., Maaker, M. de., Nederlof, I.., Kluin, R. J.., Warren, S.., Ong, Sufey., Wiersma, T.., Russell, N.., Lalezari, F.., Schouten, P.., Bakker, N.., Ketelaars, S.., Peters, Dennis., Lange, C.., Werkhoven, E. van., Tinteren, H. van., Mandjes, I.., Kemper, I.., Onderwater, Suzanne., Chalabi, M.., Wilgenhof, S.., Haanen, J.., Salgado, R.., Visser, K. D. de., Sonke, G.., Wessels, L.., Linn, S.., Schumacher, T.., Blank, C.., & Kok, M.. (2019). Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial. Nature Medicine , 25 , 920 – 928 . http://doi.org/10.1038/s41591-019-0432-4
26) Wolff, Antonio C.., Hammond, M. E.., Hicks, David G.., Dowsett, M.., McShane, Lisa M.., Allison, Kimberly H.., Allred, D.., Bartlett, John M.S.., Bilous, M.., Fitzgibbons, P.., Hanna, W.., Jenkins, Robert B.., Mangu, P.., Paik, S.., Perez, Edith A.., Press, Michael F.., Spears, Patricia A.., Vance, Gail H.., Viale, G.., & Hayes, Daniel F.. (2013). Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology , 31 31 , 3997-4013 . http://doi.org/10.1200/JCO.2013.50.9984
27) Xia, C.., Dong, Xuesi., Li, He., Cao, M.., Sun, Dianqin., He, Siyi., Yang, F.., Yan, Xiaoling., Zhang, Shaoli., Li, Ningkang., & Chen, Wanqing. (2022). Cancer statistics in China and United States, 2022: profiles, trends, and determinants. Chinese Medical Journal , 135 , 584 – 590 . http://doi.org/10.1097/CM9.0000000000002108